Endoplasmic reticulum stress-mediated apoptosis and autophagy in osteoarthritis: From molecular mechanisms to therapeutic applications Authors: Yifan Lu, Jing Zhou, Hong Wang, Hua Gao, Eryu Ning, Zhiqiang Shao, Yuefeng Hao, Xing Yang Published: 2024 ABSTRACT Osteoarthritis (OA) is characterized primarily by the degeneration of articular cartilage, with a high prevalence and disability rate. The functional phenotype of chondrocytes, as the sole cell type within cartilage, is vital for OA progression. Due to the avascular nature of cartilage and its limited regenerative capacity, repair following injury poses significant challenges. Various cellular stressors, including hypoxia, nutrient deprivation, oxidative stress, and collagen mutations, can lead to the accumulation of misfolded proteins in the endoplasmic reticulum (ER), resulting in ER stress (ERS). In response to restore ER homeostasis as well as cellular vitality and function, a series of adaptive mechanisms are triggered, including the unfolded protein response, ER-associated degradation, and ER-phagy. Prolonged or severe ERS may exceed the adaptive capacity of cells, leading to dysregulation in apoptosis and autophagy—key pathogenic factors contributing to chondrocyte damage and OA progression. This review examines the relationship between ERS in OA chondrocytes and both apoptosis and autophagy in order to identify potential therapeutic targets and strategies for prevention and treatment of OA. Introduction Osteoarthritis (OA) is a prevalent chronic degenerative joint disease, characterized by an increasing incidence due to the aging population and rising rates of obesity. OA has impacted over 500 million individuals globally, imposing significant burdens on patients, families, and society.1 Projections indicate that OA will afflict 20% of the worldwide adult population by 2030, establishing it as the primary cause of disability among the elderly.2 Common pathological manifestations of OA encompass synovitis, cartilage degeneration, subchondral bone remodeling, ligament degeneration, and alterations in surrounding muscle structure, culminating in joint space constriction, osteophyte development, and ultimately severe impairment of joint structure and function.3 Currently, there remains a deficiency in efficacious treatments for OA. Historically, clinical interventions for OA have primarily aimed at ameliorating joint pain symptoms rather than halting or reversing disease progression. In advanced stages of OA, patients may resort to joint replacement as a last resort. Consequently, there is a pressing need for further research on OA to enhance comprehension of its underlying mechanisms, identify potential therapeutic targets for the prevention and treatment of joint degeneration, and innovate novel therapeutic strategies for OA. Articular cartilage, a type of avascular connective tissue with restricted regenerative potential, consists primarily of chondrocytes and the extracellular matrix (ECM), with the ECM comprising 98% of the overall volume of articular cartilage.4 The preservation of cartilage's mechanical support and joint lubrication capabilities is contingent upon the functional integrity of the ECM. Chondrocytes, the sole resident cells in cartilage, undergo tightly regulated maintenance of their phenotype to uphold a dynamic equilibrium between anabolic and catabolic processes. Chondrocytes regulate the joint microenvironment by modulating the synthesis of key ECM constituents, including collagen type II and aggrecan, in conjunction with the expression of ECM-degrading enzymes such as matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs to preserve the optimal biomechanical characteristics of cartilage.5 The endoplasmic reticulum (ER) serves as a crucial site for folding, modification, and assembly of secretory and membrane proteins within cells. Additionally, it contributes to various physiological metabolic processes of chondrocytes, including Ca2+ storage, gluconeogenesis, lipid synthesis, and the formation of autophagic vacuoles.6 Maintaining ER homeostasis is essential for cellular processes and responses to external stimuli. Endoplasmic reticulum stress (ERS) occurs when unfolded or misfolded proteins accumulate in the ER lumen, induced by a variety of pathological factors such as inflammatory cytokines, nutritional deficiencies, oxidative stress, cellular hypoxia, and disturbances in Ca2+ levels.7 Throughout the development of OA, pathological factors such as the inflammatory microenvironment and biomechanical changes lead to abnormal degradation of the ECM and deterioration of cartilage. In response, the anabolic activity of chondrocytes is upregulated in an effort to promote cartilage homeostasis. However, the increased load on the ER during this process renders chondrocytes more susceptible to ERS. Research indicates that ERS is only present in degenerative cartilage, and not in normal, healthy articular cartilage.8 Continual ERS may lead to heightened ECM degradation and chondrocyte impairment, ultimately resulting in the deterioration of cartilage and hastening the advancement of OA.9 Upon encountering ERS, chondrocytes engage in signaling pathways to alleviate stress, restore ER homeostasis, and uphold proper protein folding, secretion, and quality control. The unfolded protein response (UPR), ER-associated degradation (ERAD), and ER-phagy are currently recognized as pivotal components in the regulatory pathways of ERS. Of the aforementioned pathways, The UPR primarily acts to suppress ER protein synthesis and promote correct protein folding, thereby serving as the principal mechanism for alleviating ERS and reinstating ER homeostasis and functionality. The ERAD and ER-phagy, on the other hand, facilitate the clearance of luminal protein aggregates and eliminate surplus ER components to sustain ER volume and mass, ultimately alleviating ERS and reinstating ER homeostasis.10, 11, 12 During the initial phases of ERS, cells activate adaptive and protective mechanisms guided by signaling sensors to safeguard against damage from external stimuli, thereby preserving cell viability and physiological functions. Prolonged stimulation, however, may result in excessive ERS, potentially contributing to the development of OA. Various investigations have demonstrated that modulation of ERS in chondrocytes can lead to alterations in apoptosis and autophagy dynamics, consequently influencing the advancement of OA.13, 14, 15 Apoptosis is a highly regulated and evolutionarily conserved mechanism of programmed cell death that plays a crucial role in various biological processes, including the maintenance of tissue homeostasis, and response to cellular damage in multicellular organisms.16 Apoptosis can be initiated by external signals or internal stressors, activating either extrinsic or intrinsic pathways that ultimately converge on the activation of the cysteinyl aspartate specific proteinase (caspase) family. Intrinsic apoptosis encompasses a diverse array of cellular stress signals, including DNA damage and ERS, which can result in alterations in mitochondrial outer membrane permeability (MOMP) and the release of cytochrome C (CytC). Conversely, exogenous apoptosis is initiated by death receptors such as Fas and TNF-related apoptosis-inducing ligand receptor.17 Research has demonstrated that heightened ERS triggers a program of chondrocyte apoptosis in the context of OA progression.18 This apoptotic process has been found to exhibit a positive association with the extent of cartilage degradation and ECM depletion in human OA tissue samples.19 The resultant chondrocyte apoptosis contributes to joint tissue damage and exacerbates inflammatory responses, thereby furthering the advancement of OA. Autophagy, recognized as a vital self-protective mechanism of cells, is also considered a key factor in the pathogenesis of OA. This highly conserved process occurs in all eukaryotic cells and involves the degradation and recycling of specific proteins and organelles through lysosomal activity. To ensure survival and optimal functionality, damaged organelles and aggregates of abnormal proteins are eliminated; this process additionally provides extra energy for the cell. Autophagy has been shown to play a significant role in preserving cartilage integrity, regulating ER homeostasis, and facilitating cellular functional repair,20, 21 and the induction of autophagy can significantly mitigate the advancement of OA. For instance, mechanical loading has been found to enhance chondrocyte proliferation and impede the pathological progression of OA by upregulating autophagy.15 Additionally, oroxin B has been shown to possess chondroprotective properties through the enhancement of autophagy, consequently alleviating OA.22 In murine models of OA, autophagy markers, including unc-51-like kinase 1 (ULK1) and microtubule-associated protein 1 light chain 3 (LC3), have been identified as significantly linked to OA. A positive correlation exists between decreased LC3 expression and ECM degradation and apoptosis, suggesting that impaired autophagy plays a role in the pathogenesis of OA.23 In the context of OA, maintaining autophagic flux equilibrium is a potential therapeutic goal. Autophagy is generally recognized for its role in promoting cell survival under stressful conditions, yet disruptions in the autophagic pathway or an overabundance of autophagic activity can lead to cellular death.24 As OA advances, the interplay between autophagy and apoptosis undergoes dynamic alterations. In the early phases of OA, autophagy is upregulated as a defensive response to safeguard chondrocytes. Conversely, in the advanced phases of OA, autophagy may be concomitantly upregulated with apoptosis, collectively exacerbating cellular death.25 Multiple studies have demonstrated that ERS can activate the autophagy pathway in chondrocytes, aiming to either restore cellular homeostasis or initiate cell death mechanisms.26, 27 In conclusion, the interconnected processes of ERS, chondrocyte apoptosis, and chondrocyte autophagy form an intricate and interrelated network within the context of OA pathogenesis. Specifically, ERS represents a cellular state of perturbation resulting from internal or external stressors, such as oxidative stress and aberrant protein synthesis, ultimately leading to ER dysfunction. As OA progresses, ERS primarily mediates cartilage degradation and inflammatory responses, while chondrocyte apoptosis emerges as a key factor.28 Following injury or exposure to inflammatory stimuli, chondrocytes have the potential to undergo apoptosis, resulting in cartilage tissue degradation and diminished joint functionality. ERS may accelerate chondrocyte apoptosis, thus consequently worsening the advancement of OA.29 Meanwhile, chondrocyte autophagy is implicated in the pathogenesis of OA. ERS can stimulate autophagic processes in chondrocytes in response to internal cellular perturbations.27 Therefore, a thorough examination of the relationship between OA, ERS, chondrocyte apoptosis, and chondrocyte autophagy suggests that ERS may contribute to the pathological alterations in bone and joint by modulating the apoptosis and autophagy processes. This cellular-level interaction provides new insight into the pathogenesis of OA and proposes potential directions for future research and treatment approaches. This review will investigate the mechanisms by which ERS influences the apoptosis and autophagy of OA chondrocytes, and will also examine potential therapeutic targets. The regulation mode of ERS The UPR pathway The UPR pathway in the ER is primarily mediated by the trans-ER membrane receptors inositol-requiring enzyme 1 (IRE1), double-stranded RNA-activated protein kinase-like ER kinase (PERK), and activating transcription factor 6 (ATF6). In the absence of external stimuli, these receptors are sequestered by the chaperone protein glucose-regulated protein 78 (GRP78) and remain inactive. However, during ERS, an abundance of unfolded proteins in the ER lumen displaces GRP78 from the receptors, leading to their activation and subsequent initiation of the UPR. To maintain ER homeostasis, the UPR pathway triggers the transcription of genes responsible for encoding chaperones and folding catalysts, inhibits global translation, induces ER membrane expansion, and initiates ERAD. These coordinated processes collectively enhance the ER's protein folding capacity, limit the influx of newly synthesized proteins into the ER, and facilitate the removal of accumulated proteins (Figure 1).Fig. 1A schematic representation of the UPR in response to ERS. The UPR signaling pathways are initiated upon the accumulation of misfolded and unfolded proteins in the ER, leading to the displacement of GRP78 from PERK, ATF6, and IRE1. This triggers downstream signaling cascades. PERK phosphorylates eIF2α, resulting in increased ER protein accumulation and decreased ATF4 mRNA translation. Subsequently, ATF4 interacts with CHOP to regulate the expression of target genes such as GADD34 and ERO-1α. GADD34 encodes a regulatory subunit of the eIF2α-directed phosphatase complex that dephosphorylates eIF2α and restores protein synthesis. The PERK pathway is well-known for its ability to induce apoptosis. During ERS, IRE1 undergoes dimerization and activation. Activated IRE1 removes an intron from XBP1, leading to the production of XBP1s, which is then transported into the nucleus, where it facilitates gene translation. Upon ERS, ATF6 translocates to the Golgi apparatus where it undergoes cleavage by S1P and S2P enzymes. This cleavage generates cytosolic fragment ATF6f which directly controls basal transcription of genes encoding ERAD components including members of bZip family as well as XBP1. This figure is created with BioRender.com. Abbreviations used: ATF4, Activating transcription factor 4; ER, Endoplasmic reticulum; ERS, Endoplasmic reticulum stress; GADD34, Growth Arrest and DNA Damage-inducible 34; IRE1, Inositol-requiring enzyme 1; PERK, Protein kinase-like ER kinase; S1P, Site-1 proteinase; S2P, Site-2 proteinase; UPR, Unfolded protein response.Fig. 1 A schematic representation of the UPR in response to ERS. The UPR signaling pathways are initiated upon the accumulation of misfolded and unfolded proteins in the ER, leading to the displacement of GRP78 from PERK, ATF6, and IRE1. This triggers downstream signaling cascades. PERK phosphorylates eIF2α, resulting in increased ER protein accumulation and decreased ATF4 mRNA translation. Subsequently, ATF4 interacts with CHOP to regulate the expression of target genes such as GADD34 and ERO-1α. GADD34 encodes a regulatory subunit of the eIF2α-directed phosphatase complex that dephosphorylates eIF2α and restores protein synthesis. The PERK pathway is well-known for its ability to induce apoptosis. During ERS, IRE1 undergoes dimerization and activation. Activated IRE1 removes an intron from XBP1, leading to the production of XBP1s, which is then transported into the nucleus, where it facilitates gene translation. Upon ERS, ATF6 translocates to the Golgi apparatus where it undergoes cleavage by S1P and S2P enzymes. This cleavage generates cytosolic fragment ATF6f which directly controls basal transcription of genes encoding ERAD components including members of bZip family as well as XBP1. This figure is created with BioRender.com. Abbreviations used: ATF4, Activating transcription factor 4; ER, Endoplasmic reticulum; ERS, Endoplasmic reticulum stress; GADD34, Growth Arrest and DNA Damage-inducible 34; IRE1, Inositol-requiring enzyme 1; PERK, Protein kinase-like ER kinase; S1P, Site-1 proteinase; S2P, Site-2 proteinase; UPR, Unfolded protein response. The ATF6 pathway The ATF6 protein, comprising both ATF6α and ATF6β isoforms, is a transmembrane protein of type II that localizes within the ER. ATF6β has the potential to function as a suppressor in order to regulate the extent and duration of gene regulation mediated by ATF6α.30 Upon ERS, ATF6 disassociates from GRP78 and is subsequently transported to the Golgi apparatus via coat protein II. The full-length ATF6 (90 kDa) undergoes cleavage by Golgi-resident processing enzymes site-1 proteinase and site-2 proteinase to release the ATF6 cytoplasmic fragment, known as ATF6f (50 kDa).31 The ATF6f protein possesses a basic leucine zipper transcription factor domain, which translocates to the nucleus upon recognition of nuclear localization signals. This particular protein then regulates the activity of multiple genes associated with the ERS response, such as C/EBP homologous protein (CHOP), which plays a role in promoting cell death, and proteins involved in the degradation of misfolded proteins within the ERAD pathway. These genes are responsible for initiating the transcription of ERS response element (ERSE) genes and controlling the expression of molecular chaperones, including GRP78, GRP94, and calreticulin, as well as folding factors such as protein disulfide isomerase family A member 4 and regulating the transcription of X-box binding protein 1 (XBP1). Consequently, the pathways involved in ER protein folding, trafficking, and degradation are impacted.32 The research findings have indicated that the interaction between ATF6f and XBP1 can stimulate an upregulation in the expression of proteins associated with ERAD.33 The IRE1 pathway IRE1 is characterized as an ER-resident type I transmembrane protein with a kinase domain located in the cytosol and an endonuclease domain within the ER. Upon activation by oligomerization and phosphorylation, IRE1 mediates the unconventional cleavage of XBP1 mRNA through its endonuclease activity, generating the active transcription factor known as spliced XBP1 (XBP1s).34 It regulates the expression of multiple folding enzymes, oxidoreductases, glycosylases, intracellular transport components, and ERAD-related proteins. Additionally, it governs the activation of UPR target genes, regulates protein trafficking and lipid synthesis, as well as orchestrates various mechanisms involved in protein folding to restore homeostasis within the ER.35 The ribonuclease activity of IRE1α targets not only XBP1 RNA, but also participates in a process known as regulated IRE1-dependent decay, which involves the cleavage and subsequent exonuclease-mediated degradation of specific mRNAs or microRNAs. The ultimate outcome of this process is a decrease in mRNA abundance and a reduction in the protein folding burden within the ER.36 The PERK pathway The PERK protein is a transmembrane protein of type I that is localized in the ER. It consists of an ER lumen stress-sensing domain, a transmembrane segment, and a cytoplasmic kinase domain. The dissociation of PERK's ER domain from GRP78 facilitates autodimerization and autophosphorylation, leading to specific phosphorylation of eukaryotic initiation factor 2α (eIF2α) at Ser51 by PERK. This results in decreased activity of eIF2α. This impediment in initiating the translation of proteins hinders the synthesis of new proteins in the ER. Phosphorylated eIF2α facilitates the selective translation of mRNA encoding, activating transcription factor 4 (ATF4), a member of the basic leucine zipper protein family that can directly enhance the expression of CHOP. Consequently, ATF4 and CHOP collaboratively stimulate the expression of diverse genes associated with apoptosis, autophagy, amino acid metabolism, and antioxidant response. ATF4 is additionally engaged in a significant feedback mechanism that facilitates the dephosphorylation of eIF2α by up-regulating Growth Arrest and DNA Damage-inducible 34 (GADD34), a regulatory subunit of a phosphatase enzyme, ultimately leading to the restoration of protein translation.37 The link between UPR and OA Following OA, signaling pathways related to the UPR are initiated, leading to alterations in gene expression and metabolism that prompt cellular stress responses and pathophysiological processes. The upregulation of ATF6 post-OA enhances the transcription of ERS-related genes.38 Elevated levels of CHOP expression contribute to cell apoptosis and inflammatory responses,39 while increased expression of GRP78 during OA serves to uphold cellular homeostasis.8 IRE1α knockdown notably increased ERS-induced chondrocyte apoptosis, suggesting that IRE1α is essential for the inhibition of chondrocyte apoptosis during ERS.40 Additionally, PERK serves as the primary regulatory molecule of the UPR. Direct inhibition of PERK expression can lower ERS levels and exhibit a significant protective effect on chondrocytes, thereby slowing down the progression of OA.15 Research has demonstrated that the absence of CHOP leads to a reduction in ERS within chondrocytes derived from mice with OA. This decrease effectively impedes chondrocyte apoptosis and dysfunction, resulting in a significant delay in cartilage degeneration.41, 42 In addition, a separate study revealed that the overexpression of ATF6 in chondrocytes affected by OA resulted in an enhanced expression of XBP1s through the IRE1α pathway. This process effectively suppressed ERS-induced apoptosis of chondrocytes and degradation of the ECM.38 Collectively, targeting the UPR offers a promising therapeutic strategy for OA. Enhanced comprehension of the mechanism of action underlying the UPR and investigation into the precise gene alterations implicated will support the advancement of more targeted therapies for OA. UPR serves as a cellular self-protective mechanism to adapt to changing conditions, with its ability to restore ER homeostasis contingent upon the intensity and duration of the stimulus. In cases of mild ERS, activation of the UPR response can shield cells from harm and promote cell survival43; Moreover, the activated UPR can induce autophagy to eliminate misfolded proteins that exceed the proteases' clearance capacity, thereby restoring balance in the ER and enhance cellular viability44; Conversely, under conditions of prolonged or severe ERS that cannot be resolved promptly, the UPR may trigger cell apoptosis through its distinctive apoptotic pathway or induce autophagic cell death via excessive autophagy activation.45, 46 The ERAD pathway ERAD and UPR exhibit both independent and cooperative relationships in the context of protein folding and degradation processes.47 UPR functions to enhance protein folding by increasing the expression of molecular chaperones and folding enzymes through intracellular signal transduction pathways. In contrast, ERAD is responsible for the removal of misfolded proteins from the ER to the cytoplasm for degradation via the ubiquitin-proteasome system. The ERAD process encompasses several crucial stages, including identification of substrates, retrograde translocation, attachment of ubiquitin molecules, and subsequent proteasomal degradation (Figure 2).48Fig. 2A schematic representation of the steps and proteins involved in ERAD. The ERAD process in mammals includes the identification of improperly folded proteins through OS9/XTP3-B, which are subsequently directed to the HRD1 complex, a ubiquitin ligase. Subsequently, HRD1 assists in transporting the substrate to the cytosolic side of the ER through a reverse transport channel. The VCP-UFD1-NPL4 heterotrimer then processes it for ubiquitination before directing it toward degradation by the proteasome. This figure is created with BioRender.com. Abbreviations used: ER, Endoplasmic reticulum; ERAD, ER-associated degradation.Fig. 2 A schematic representation of the steps and proteins involved in ERAD. The ERAD process in mammals includes the identification of improperly folded proteins through OS9/XTP3-B, which are subsequently directed to the HRD1 complex, a ubiquitin ligase. Subsequently, HRD1 assists in transporting the substrate to the cytosolic side of the ER through a reverse transport channel. The VCP-UFD1-NPL4 heterotrimer then processes it for ubiquitination before directing it toward degradation by the proteasome. This figure is created with BioRender.com. Abbreviations used: ER, Endoplasmic reticulum; ERAD, ER-associated degradation. The protein complex SEL1L-HRD1 is an extensively conserved constituent of the ERAD mechanism in mammals, where SEL1L functions as a coenzyme for HRD1, an E3 ubiquitin ligase. Prior to being guided toward ERAD adapters like SEL1L, unfolded nascent polypeptide substrates within the ER are recognized by molecular chaperones like GRP78 and lectins, including OS9 and XTP3-B. During the initiation of ERAD, GRP78 recognizes and binds to exposed hydrophobic regions of misfolded proteins, thereby preventing their premature aggregation.49 OS9 and XTP3-B function as a 'gatekeeper' for the retro-translocation device, ensuring that the protein enters the ERAD pathway only after an unsuccessful folding attempt. Notably, XTP3-B has been shown to significantly inhibit the degradation of non-glycoproteins, with this inhibition being antagonized by OS9, indicating a subtle reciprocal regulation within the ERAD pathway.50 Subsequently, these substrates are translocated to the cytosolic side of the ER through specific channels, such as HRD1 and DER1, and then polyubiquitinated. The ternary complex comprising VCP-UFD1-NPL4 facilitates ATP-dependent degradation by transporting ubiquitinated substrates from the ER to the proteasome.12 Disruption of SEL1L has been shown to disturb ER homeostasis, induce ERS, inhibit protein synthesis, and trigger cell death in SEL1L knockout models.51 Therefore, the ERAD mechanism is crucial for preserving ER homeostasis and cellular physiological processes. Chondrocytes secrete a substantial quantity of ECM molecules that undergo production, folding, and modification within the ER. Consequently, ERAD plays a pivotal role in the establishment and maintenance of cartilage homeostasis. Research52 showed that the activity of ERAD genes was notably elevated during the chondrogenesis phase, while its activity was notably down-regulated in affected cartilage detected in patients diagnosed with OA. Dysfunction of the ERAD pathway may lead to aberrant accumulation of ECM molecules within chondrocytes, resulting in developmental defects in chondrogenesis in embryos and damage to articular cartilage in mature individuals. The inefficiency of ERAD in removing certain misfolded proteins can be attributed to factors such as lack of recognition by ERAD factors like GRP78, excessive molecular weight, and a propensity to form aggregates or polymers that hinder retro-translocation. In such cases, these proteins may be eliminated through ER-to-lysosome-associated degradation (ERLAD).53 During ERLAD, lysosomes have the ability to directly fuse with vesicles derived from the ER and degrade them.54 The collaborative actions of ERAD and ERLAD effectively cooperate to eliminate misfolded proteins within the ER, thereby contributing significantly to the maintenance of ER homeostasis. The ER-phagy pathway The participation of ER-phagy becomes necessary in instances where the UPR and ERAD mechanisms are insufficient to manage the excessive buildup of proteins within the ER. ER-phagy, a selective autophagic process responsible for orchestrating ER fragmentation and directing it toward lysosomal degradation, was initially identified and termed by Bernales et al. during their investigation of UPR.55 Currently, research on ER-phagy is primarily focused on macroautophagy, which involves a series of steps: (1) ER-phagy receptors interact with the autophagy bilayer via functional domains such as LC3, Atg8, and GABARAP to remove debris from the ER; (2) the double-membrane of autophagy encapsulates some fragments of ER to form autophagosomes; (3) autophagosomes merge with lysosomes; and (4) the lysosomal degradation process commences. ER-phagy plays a crucial role in regulating ER mass and capacity to uphold its structural and functional equilibrium.56 Intracellular ER-phagy is typically maintained at a basal level under physiological conditions but is notably upregulated in response to stimuli such as ERS or nutrient deprivation.57 Six receptors, including FAM134B, RTN3L, SEC62, ATL3, CCPG1, and TEX264, participate in ER-phagy in mammals. Each of these receptors is characterized as an ER membrane protein with a minimum of one LC3-interacting region/GABARAP-interacting region (GIR) domain. The receptor has the ability to interact with the LC3/GABARAP family proteins found in mammalian autophagosomes, resulting in the accumulation of LC3 around fragmented ER. This process leads to the formation of autophagosomes surrounding the ER fragments and reticulin, ultimately promoting the selective fragmentation of the ER. Subsequently, the fragmented components are conveyed to lysosomes for disintegration and reuse. While each of these receptors is capable of facilitating ER-phagy, the activation mechanisms vary. For instance, FAM134B, RTN3L, ATL3, and TEX264-mediated ER-phagy can be induced by starvation, while CCPG1-mediated ER-phagy is activated by ERS, and SEC62 primarily serves as an ER-phagy receptor during ERS recuperation.58, 59, 60, 61 Remodeling of the ER through ER-phagy may play a significant role in the regulation of protein secretion in chondrocytes, particularly during the process of hypertrophic chondrocyte differentiation. Research has shown that fibroblast growth factor 18 specifically induces ER-phagy by activating TFEB/TFE-dependent transcriptional regulation of FAM134B in chondrocytes. This mechanism is crucial for endochondral ossification and the development of bone tissue.62 Currently, research on ER-phagy and its implications for disease primarily centers on tumors and nervous system disorders, with a lack of specific studies on chondrocyte ER-phagy in the context of OA. Given the significant role of the ER in chondrocyte-mediated ECM synthesis and secretion, as well as the impact of ECM homeostasis on OA development, the significance of ER-phagy in the pathogenesis of OA is currently undervalued and warrants further investigation in future studies. Mechanisms of ERS-mediated chondrocyte apoptosis in OA In addition to the established exogenous (death receptor) and endogenous (mitochondrial) pathways of apoptosis, numerous studies have identified the ER as playing a distinct role in the cellular apoptosis process. Consequently, the ERS-induced apoptotic pathway has emerged as a novel focus of research interest. This pathway represents a normal pathophysiological response to excessive stress. When the UPR is unable to alleviate ERS promptly, the downstream proteins of PERK, ATF6, and IRE1, including activating transcription factors ATF4, XBP-1, and GADD153, exhibit elevated expression levels. This leads to the disruption of ER function, induction of cell apoptosis, and ultimately serves as a protective mechanism against detrimental cellular damage within the cartilage tissue.7 Currently, research indicates that the process of ERS-mediated apoptosis primarily involves the UPR and Ca2+ signaling pathways (Figure 3). Upon intense or prolonged ERS, the accumulation and activation of PERK, ATF6, and IRE1 trigger downstream apoptotic signaling molecules, including CHOP, c-Jun N-terminal kinase (JNK), members of the caspase family, and members of the B-cell lymphoma-2 (BCL-2) family, ultimately resulting in cell apoptosis. CHOP plays a crucial function in facilitating apoptosis by synthesizing proteins as a response to the cellular stress caused by unfolded proteins.63 Several studies have indicated that CHOP may diminish the anti-apoptotic capacity of cells through downregulation of BCL-2 expression and depletion of glutathione, while BCL-2 is known to modulate Ca2+ homeostasis within the ER and trigger apoptosis.64 Furthermore, ERS can lead to the activation of the JNK pathway by phosphorylated IRE1, which in turn interacts with the receptor protein TRAF2 to initiate a cascade of phosphorylation events that ultimately facilitate cell apoptosis.65Fig. 3A schematic representation of ERS-induced apoptosis. The induction of ERS-mediated apoptosis involves four major pathways, namely PERK, IRE1α, ATF6, and Ca2+. Among these pathways, the CHOP pathway plays a pivotal role in driving apoptosis, while all three transmembrane sensors can trigger apoptotic responses. Additionally, ERS can also induce apoptosis through the IRE1α-TRAF2-JNK pathway. Perturbation of Ca2+ homeostasis leads to calpain activation and subsequent formation of mitochondrial permeability transition pores. Subsequent release of CytC as a consequence of this cascade event ultimately activates the mitochondrial apoptotic program. This figure is created with BioRender.com. Abbreviations used: ATF6, Activating transcription factor 6; CHOP, C/EBP homologous protein; ERS, Endoplasmic reticulum stress; IRE1, Inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase; PERK, Protein kinase-like ER kinase.Fig. 3 A schematic representation of ERS-induced apoptosis. The induction of ERS-mediated apoptosis involves four major pathways, namely PERK, IRE1α, ATF6, and Ca2+. Among these pathways, the CHOP pathway plays a pivotal role in driving apoptosis, while all three transmembrane sensors can trigger apoptotic responses. Additionally, ERS can also induce apoptosis through the IRE1α-TRAF2-JNK pathway. Perturbation of Ca2+ homeostasis leads to calpain activation and subsequent formation of mitochondrial permeability transition pores. Subsequent release of CytC as a consequence of this cascade event ultimately activates the mitochondrial apoptotic program. This figure is created with BioRender.com. Abbreviations used: ATF6, Activating transcription factor 6; CHOP, C/EBP homologous protein; ERS, Endoplasmic reticulum stress; IRE1, Inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase; PERK, Protein kinase-like ER kinase. The CHOP pathway The protein CHOP, encoded by the DNA damage-inducible transcript 3 (DDIT3) gene, serves a pivotal function in the UPR and is widely recognized as a key regulator of ERS-induced apoptosis.66 The presence of CHOP is typically observed at low levels under normal physiological conditions, but its concentration significantly increases upon ERS, indicating inducible expression. Knocking out the DDIT3 gene in cells results in decreased protein aggregation in the ER during ERS, leading to reduced levels of oxidative stress and apoptosis.67, 68, 69, 70 This phenomenon does not manifest in the absence of knockout of any other UPR genes. The three signaling pathways, PERK, ATF6, and IRE1, have the ability to induce the transcription of CHOP, with the PERK-eIF2α-ATF4 pathway being essential for CHOP transcription.66 Numerous CHOP target genes, such as GADD34, ER oxidase 1α (ERO1α), BCL-2, and death receptor 5 (DR5), have been identified and are involved in the regulation of cell apoptosis.67, 71 GADD34 mediates the activation of protein phosphatase 1 and subsequent dephosphorylation of eIF2α, thereby counteracting the translation inhibition induced by eIF2α phosphorylation.72 This reversal of translational repression is crucial for the restoration of protein synthesis and resolution of unfolded protein accumulation under conditions of ERS. However, this process also facilitates the translation of mRNAs encoding pro-apoptotic proteins, ultimately leading to ATP depletion, heightened oxidative stress, and the potential initiation or enhancement of apoptosis upon overexpression of GADD34.73, 74 Multiple studies have provided evidence that salubrinal, a compound that inhibits the dephosphorylation of eIF2α, shows promise in mitigating chondrocyte apoptosis and ameliorating the deterioration of cartilage in experimental animal models with OA.75, 76 ERO1α plays a significant role as a catalyst during the oxidative folding process of secreted proteins, leading to the generation of H2O2 as an additional byproduct. In conditions of ERS, ERO1α is upregulated in a manner dependent on CHOP, thereby amplifying the generation of reactive oxygen species (ROS) within the ER lumen.67 This upregulation subsequently triggers inositol-1,4,5-trisphosphate receptor (IP3R)-mediated Ca2+ efflux from the ER.77 Ca2+ released from the ER are transported into mitochondria via mitochondrial-associated ER membranes.78 Enhanced production of ROS, initiation of the mitochondrial permeability transition pore, liberation of CytC, and ultimately triggering apoptosis in chondrocytes can be attributed to the accumulation of Ca2+ within the mitochondrial matrix.79 One potential mechanism through which CHOP induces apoptosis is by reducing the levels of antiapoptotic proteins from the BCL-2 family,80 while simultaneously increasing the transcriptional expression of several pro-apoptotic proteins, such as BIM, a protein containing the BH3-only domain. This ultimately leads to apoptosis that is dependent on BCL-2 associated X protein (BAX) and BCL-2 antagonist/killer 1 (BAK).81 One gene induced by CHOP is tribbles homologue 3 (TRB3). Research has demonstrated the presence of TRB3 in human chondrocytes, with elevated levels observed in OA cartilage and isolated OA chondrocytes, indicating a potential role for increased TRB3 in promoting apoptosis in OA cartilage.82 Functional investigations of TRB3 have demonstrated its capacity to trigger apoptosis by interfering with the activation of the pro-survival serine/threonine kinase protein kinase B (AKT), impeding its phosphorylation and reducing its enzymatic activity.83, 84 The activation of AKT has a protective effect on chondrocytes by mitigating ERS-induced apoptosis through upregulation of the anti-apoptotic protein BCL-XL and inhibiting caspase-3 activity.85 Additionally, it has been proposed that TRB3 acts as both a target and regulator of CHOP, with TRB3 potentially modulating CHOP signal transduction via a negative feedback loop.86 Additional investigation is necessary to clarify the specific function of TRB3 in ERS-induced apoptosis. The JNK pathway The JNK signaling pathway plays a critical role in the regulation of cellular survival and apoptosis. It has been noted that temporary stimulation of JNK promotes cellular proliferation, whereas prolonged activation leads to apoptosis.87 In the context of ERS, activated IRE1 interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2) to recruit apoptosis signal-regulating kinase 1 (ASK1), forming an IRE1/TRAF2/ASK1 trimer. Subsequently, downstream stress kinases such as JNK and p38 mitogen-activated protein kinase (p38 MAPK) are activated, promoting apoptosis.88 Following its activation, JNK relocates to the nucleus from the cytoplasm and initiates the apoptotic pathway of death receptors by activating transcription factors such as c-Jun, c-Fos, EIK-1 and inducing the expression of TNF, Fas-L and other ligands.89 Concurrently, the activated JNK also triggers the mitochondrial apoptotic pathway through the up-regulation of pro-apoptotic proteins, such as BAX and BAK, by enhancing the expression of BCL-2 interacting mediator of cell death (BIM) and BCL-2 homology 3 interacting domain death agonist (BID) in the cytoplasm.90, 91, 92 In addition, p38 MAPK phosphorylates and triggers the activation of the transcription factor CHOP, leading to modifications in the expression of genes related to cell apoptosis. These alterations include elevated levels of BIM and DR5, as well as reduced levels of BCL-2,93 ultimately facilitating apoptosis. Elevated levels of both active JNK and active p38 MAPK were observed in human OA cartilage compared to normal cartilage, indicating the potential involvement of this pathway in the cell death of articular chondrocytes.94, 95 The caspase-12 pathway At least 15 caspase proteins have been identified in mammals, with caspase-12 showing the closest association with the ERS apoptosis pathway. This pathway is a specific signaling cascade for apoptosis within the ER. In normal physiological conditions, caspase-12 is localized to the ER membrane, where it interacts with TRAF2. However, under sustained ERS stimulation, TRAF2 disassociates from caspase-12, facilitating the activation of caspase-12. This activated caspase-12 then translocates from the ER membrane to the cytoplasm, subsequently activating caspase-9 and caspase-3 in a sequential manner, ultimately leading to cell apoptosis. The activation of caspase-9 was found to be independent of apoptotic peptidase activating factor 1 (Apaf-1) and CytC, key components of the mitochondrial apoptosis pathway.96, 97, 98 An alternative mechanism proposed for the activation of caspase-12 involves the release of Ca2+ from the ER, leading to the activation of calpain in the cytoplasm, facilitating its translocation to the ER for caspase-12 cleavage and subsequent activation.99 Previous research has indicated that ERS not only upregulates the expression of caspase-12 but also facilitates the translocation of cytoplasmic caspase-7 toward the ER membrane, thereby triggering the activation of caspase-12.100 Cells lacking caspase-12 were observed to exhibit resistance to ERS-induced apoptosis,101 while other apoptotic stimuli were still able to induce cell death. These findings suggest that caspase-12 is predominantly implicated in apoptosis triggered by ERS, as opposed to apoptosis triggered by non-ERS stimuli.101, 102 Ca2+-mediated apoptosis As a crucial second messenger in intracellular signal transmission, Ca2+ functions as a signal molecule with significant implications for various cellular activities. The ER serves as a pivotal location for both the storage of Ca2+ reserves and the facilitation of signal transduction. The maintenance of intracellular Ca2+ homeostasis is predominantly regulated by the ER. The release of Ca2+ from the ER and its concentration within the cytosol are integral factors in ERS-induced apoptosis.103 In the resting state, there is a higher concentration of Ca2+ in the ER lumen compared to the cytosol. This gradient is maintained by three channels located on the ER membrane that are responsible for both the uptake and release of Ca2+. Specifically, the ryanodine receptor and IP3R predominantly release Ca2+ into the cytosol,104 whereas the sarcoplasmic/ER Ca2+-ATPase pump facilitates the transport of Ca2+ back to the ER lumen.105 Disruption of the aforementioned Ca2+ channels may lead to an imbalance of Ca2+ in the ER lumen. In most cases, ERS results in the mobilization of Ca2+ from the ER lumen, causing an elevation in cytosolic Ca2+ levels.106 Upon surpassing a certain threshold, the increased cytosolic Ca2+ triggers the permeabilization of the mitochondrial outer membrane and restructuring of the mitochondrial ridges,107 leading to the release of pro-apoptotic factors such as CytC from the intermembrane and ridge spaces. Subsequently, this process activates both caspase-dependent and caspase-independent signaling pathways, culminating in the initiation of the apoptotic program. Significantly, the activation of Calpain occurs in response to an imbalance of ER Ca2+ levels, resulting in an increase in cytosolic free Ca2+. Once activated, Calpain translocates from the cytoplasm to the ER membrane, where it processes and activates caspase-12, initiating a cascade of caspase activation that ultimately leads to apoptosis.99, 108 This section will delve into the two pathways through which Ca2+ mediates apoptosis: those involving BCL-2 proteins and IP3R. The BCL-2 cytoplasmic protein family is widely recognized for its crucial role in regulating apoptosis. Within this family, certain proteins such as BAX, BAK, and BCL-XL/BCL-2 associated death promoter are recognized for their pro-apoptotic functions, while others like BCL-2 and BCL-XL exhibit anti-apoptotic properties. In the context of ERS, BH3-only proteins like BIM, BID, and PUMA utilize their BH3 domain to counteract the anti-apoptotic effects of BCL-2 proteins and directly trigger conformational alterations in pro-apoptotic BAX and BAK. This leads to the exposure of the N and C termini of these proteins, their localization to the mitochondria, and the subsequent formation of oligomeric pores in the mitochondrial outer membrane that promote MOMP and the release of proteins from the intermembrane space into the cytosol. CytC interacts with the adapter protein Apaf1 to assemble the apoptosome complex.109 This complex then binds and activates caspase-9, an initiator in the apoptotic pathway, which subsequently triggers the cleavage and activation of caspase-3, ultimately leading to programmed cell death.110 Additionally, the release of proteins such as the second mitochondria-derived activator of caspase and high-temperature factor 2 during MOMP inhibits the caspase inhibitor X-linked inhibitor of apoptosis protein, thereby facilitating apoptosis. The exogenous apoptotic pathway interacts with the endogenous pathway through the caspase-8-mediated cleavage of BID, resulting in the production of truncated BID, which effectively triggers MOMP. CytC plays a crucial role in activating caspases, ultimately leading to apoptosis.111 It is important to note that cells with disrupted or blocked caspase activation may still undergo cell death via MOMP, known as caspase-independent cell death. Hence, MOMP is regarded as a crucial stage indicating the irreversible initiation of apoptosis implementation.112 The apoptotic process triggered by ERS is intricately linked to both the exogenous death receptor pathway and the endogenous mitochondrial pathway, Requiring additional exploration into the intricate fundamental mechanisms. During ERS, the IP3 receptor facilitates the release of Ca2+ from the ER to the vicinity of mitochondria through the formation of contact sites known as mitochondria-associated membranes.113 The accumulation of Ca2+ in mitochondria triggers the opening of the mitochondrial permeability transition pore in the inner membrane, resulting in increased mitochondrial membrane permeability. This process leads to matrix swelling, outer membrane rupture, and the release of pro-apoptotic agents, particularly CytC.114 It has been suggested that the release of CytC from mitochondria may subsequently stimulate IP3R located on the ER membrane, leading to the release of Ca2+ and ultimately initiating the apoptotic pathway through a positive feedback mechanism.115 ERS and autophagy in OA chondrocytes Overview of autophagy Autophagy is a cellular process that facilitates the degradation of damaged or senescent organelles, proteins, and invading pathogens to uphold cellular homeostasis. Autophagy is a crucial process that remains consistently operational in cartilage that is in good health, and it serves as an essential mechanism for preserving the proper functioning of chondrocytes. However, the decline in chondrocyte autophagy activity associated with aging results in compromised cellular and tissue equilibrium, ultimately contributing to the emergence of structural abnormalities within joints.116 Autophagy can be categorized into three distinct types depending on the degradation mechanism employed: macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy, a highly conserved process in evolution, involves the formation of autophagosomes that encapsulate degradation substrates within a bilayer membrane-like vesicle structure. Subsequently, these autophagosomes fuse with lysosomes for efficient degradation. Microautophagy refers to the direct invagination of lysosomal or vacuolar membranes around substrates for degradation. In contrast, chaperone-mediated autophagy involves molecular chaperones—typically the heat shock cognate 70 kDa protein, which recognizes substrates containing the KFERQ-like motif—transporting components designated for degradation to the lysosome.117 These components then enter the lysosome via specific receptor proteins located on its membrane for degradation. Neither microautophagy nor chaperone-mediated autophagy involves autophagosomes.118 The three aforementioned types of autophagy are crucial for the maintenance of cellular equilibrium and overall bodily health. Among these, macroautophagy is the most extensively researched. In the context of OA studies, autophagy typically refers to macroautophagy unless otherwise specified. The autophagic process can be delineated into five key stages: initiation, nucleation of phagosomes, maturation of autophagosomes, fusion of autophagosomes with lysosomes, and degradation of contents (Figure 4). These stages are facilitated by a range of autophagy-related genes (ATG) proteins.119 Autophagy is initiated through the action of the ATG1/ULK1 kinase complex,120 which subsequently interacts with the phosphoinositide 3-kinase (PI3K) complex composed of Vps15, Vps34, and Beclin-1 to form phagosomes.121 The ATG5-ATG12-ATG16 complex, in conjunction with lipid-derived microtubule-associated protein 1 light chain 3 II (LC3-II), facilitates phagosome elongation to generate autophagosomes.122 These autophagosomes then merge with lysosomes to create autolysosomes for the degradation of their contents.123 Beclin-1 and LC3-II serve as key regulators of autophagy, with Beclin-1 facilitating the nucleation of autophagosomes and promoting their maturation in conjunction with LC3-II.124 The crucial role of the mammalian target of rapamycin (mTOR) in autophagy is apparent, with AKT and mitogen-activated protein kinase (MAPK) factors activating the mTOR signaling pathway in conditions of adequate nutrition, thereby inhibiting the formation of the ULK1 complex and subsequently suppressing the initiation of autophagy.125 The AMP-activated protein kinase (AMPK) serves as a stimulator of autophagy by activating the ULK1 complex and PI3K complex to initiate autophagosome formation, while also inhibiting mTOR to enhance autophagy. Impairment of AMPK function is linked to diminished autophagy, compromised mitochondrial activity, heightened ROS generation, and inflammation of joint tissues, ultimately resulting in deterioration of articular cartilage and synovial inflammation, thereby facilitating the progression of OA.126Fig. 4A schematic diagram illustrating the macroautophagy process. ERS can induce autophagy through the AMPK/mTOR and PI3K/AKT/mTOR pathways, leading to the generation of autophagosomes. The autophagosome degrades the internal cellular material upon fusion with the lysosome. This figure is created with BioRender.com. Abbreviations used: AMPK, AMP-activated protein kinase; ERS, endoplasmic reticulum stress; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide3-kinase.Fig. 4 A schematic diagram illustrating the macroautophagy process. ERS can induce autophagy through the AMPK/mTOR and PI3K/AKT/mTOR pathways, leading to the generation of autophagosomes. The autophagosome degrades the internal cellular material upon fusion with the lysosome. This figure is created with BioRender.com. Abbreviations used: AMPK, AMP-activated protein kinase; ERS, endoplasmic reticulum stress; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide3-kinase. Autophagy has been identified as a mechanism that can alleviate ERS by removing accumulated misfolded proteins.127 In contrast to ERAD facilitated by the ubiquitin-proteasome system, autophagy has the capability to degrade a wide array of long-lived proteins and organelles, including the ER, mitochondria, peroxisomes, nucleus, and ribosomes.128, 129, 130 Both autophagy and ERAD play crucial roles in maintaining protein homeostasis and ensuring quality control. Autophagy at basal levels plays a crucial role in degrading damaged proteins and organelles, as evidenced by enhanced ERS, decreased proliferation and differentiation, and heightened apoptosis observed in autophagy-deficient mouse chondrocytes.131 The accumulation of misfolded proteins in the ER activates the UPR, leading to the upregulation of proteins involved in the recovery process and the facilitation of autophagosome formation and transport in an ATG-dependent manner. Utilizing tunicamycin to induce ERS in human chondrocytes, a notable elevation in the expression of autophagy-related proteins within chondrocytes was observed. These results indicate that ERS has the potential to induce autophagy, whereas increased autophagic activity can alleviate ERS.26 ERS regulates autophagy There are four main molecular mechanisms of ERS-mediated autophagy: ERS regulates autophagy through the PERK/eIF2α pathway, ERS regulates autophagy through IRE1, ERS regulates autophagy through ATF6, and intracellular Ca2+ concentration mediates the interaction between ERS and autophagy (Figure 5).Fig. 5A schematic diagram of ERS regulating autophagy through four pathways. ERS primarily regulates autophagy through four pathways: PERK, ATF6, and Ca2+, with the central regulator being CHOP. Upon activation of ERS, IRE1α interacts with Beclin1 via the TRAF2 and JNK pathway to enhance autophagy. ATF6 initiates the activation of DAPK, which in turn triggers autophagy via Beclin1. All three UPR pathways possess the capacity to modulate autophagy through the induction of CHOP protein expression. Furthermore, Ca2+ can also participate in the regulation of autophagy by engaging PKC and CAMKK. This figure is created with BioRender.com. Abbreviations used: ATF6, activating transcription factor 6; ERS, endoplasmic reticulum stress; IRE1, inositol-requiring enzyme 1; PERK, protein kinase-like ER kinase.Fig. 5 A schematic diagram of ERS regulating autophagy through four pathways. ERS primarily regulates autophagy through four pathways: PERK, ATF6, and Ca2+, with the central regulator being CHOP. Upon activation of ERS, IRE1α interacts with Beclin1 via the TRAF2 and JNK pathway to enhance autophagy. ATF6 initiates the activation of DAPK, which in turn triggers autophagy via Beclin1. All three UPR pathways possess the capacity to modulate autophagy through the induction of CHOP protein expression. Furthermore, Ca2+ can also participate in the regulation of autophagy by engaging PKC and CAMKK. This figure is created with BioRender.com. Abbreviations used: ATF6, activating transcription factor 6; ERS, endoplasmic reticulum stress; IRE1, inositol-requiring enzyme 1; PERK, protein kinase-like ER kinase. ERS regulates autophagy through the ATF6 pathway In cases of excessive ERS, ATF6 triggers the activation of death-associated protein kinase (DAPK), a calmodulin-regulated serine/threonine protein kinase. Activated DAPK then phosphorylates Beclin-1, causing its release from the Beclin-1/BCL-2 complex and subsequent activation of autophagy.127 ATF6 was found to inhibit the phosphorylation of AKT at Ser473 through the up-regulation of GRP78 expression, consequently suppressing the downstream mTOR activity and promoting autophagy.132 Additionally, ATF6f has the capability to indirectly modulate autophagy by inducing the expression of UPR target genes like XBP1 and CHOP, as well as directly enhancing the transcription of autophagy-related genes such as LC3, ATG3, ATG12, and ATG5. Considering the limited research on the ATF6 pathway in autophagy, further comprehensive and in-depth investigations are warranted. ERS regulates autophagy through PERK/eIF2α pathway The activation of PERK leads to the phosphorylation of downstream eIF2α, thereby enhancing the translation of certain mRNAs, such as ATF4. Following nuclear translocation, ATF4 promotes the transcription of autophagy-related genes, including CHOP, ATG proteins, and molecular chaperones like GRP78. Notably, research has shown that GRP78 may promote autophagy in chondrocytes by inhibiting mTOR activity.133 The PERK/eIF2α/ATF4 pathway leads to the upregulation of a series of proteins, including CHOP and Sestrin-2 (SESN2), which are crucial for the regulation of autophagy.134, 135 CHOP has been shown to increase TRB3 expression.86 A recent study demonstrated that TRB3 levels were markedly elevated in patients with OA, and in vitro knockdown of TRB3 effectively reversed the reduced levels of autophagy and cellular senescence in human chondrocytes.136 This rescue mechanism may be attributed to the interaction between TRB3 and the autophagy protein p62, which disrupts its binding to ubiquitin-labeled substrates and LC3, resulting in the accumulation of p62 protein and inhibition of autophagy. A separate study conducted on human OA chondrocytes82 revealed that increased expression of TRB3 resulted in the inhibition of AKT phosphorylation, leading to decreased chondrocyte survival and proteoglycan synthesis. This phenomenon may be attributed to TRB3's ability to enhance mTOR activity by modulating the AKT-mTOR pathway, ultimately suppressing autophagy.125 In chondrocytes, CHOP has the capability to decrease ATP levels, activating AMPK,137 which can then inhibit mTOR activity138 or directly trigger ULK1139 to initiate autophagy. SESN2 represents a component of the evolutionarily conserved stress-responsive SESN family, known for its role in enhancing cellular resilience during stressors. Notably, heightened SESN2 levels have been shown to trigger autophagy via AMPK activation.140 Investigations have revealed a marked decrease in SESN protein family expression within both human and murine osteoarthritic cartilage. Depletion of SESN leads to diminished chondrocyte viability, whereas augmentation of SESN levels fosters enhanced autophagic activity and cell survival in chondrocytes.141 ERS regulates autophagy through IRE1α The activated form of IRE1 is capable of recruiting TRAF2, which leads to the activation of ASK1 and the formation of a complex with TRAF2. This complex subsequently activates the downstream signal of JNK, a stress kinase known to induce either autophagy or apoptosis.88, 142 In the early stages of ERS, JNK-mediated phosphorylation of BCL-2 results in the fragmentation of the Beclin1/BCL-2 complex and the release of Beclin1. This released Beclin1 then forms the PI3KC3 complex, which promotes phagosome nucleation and activates autophagy.143, 144 The activation of the downstream p38 MAPK via the TRAF2-ASK1 pathway has been shown to indirectly induce autophagy by increasing CHOP expression. Furthermore, the transcription factor XBP1, regulated by IRE1α, triggers autophagy through the transcriptional upregulation of Beclin1.145 ERS regulates autophagy through Ca2+ The ER serves as a reservoir for cellular Ca2+, with the release of Ca2+ from the ER into the cytoplasm during stress conditions capable of inducing autophagy. The protein kinase mTOR plays a crucial role in negatively regulating autophagy by phosphorylating ATG13 to prevent autophagosome formation. Various Ca2+ mobilizers, including ions, mycin, ATP (via purine receptors), and thapargargin (an irreversible inhibitor of sarcoplasmic/ER Ca2+-ATPase), have been demonstrated to suppress mTOR activity and induce the accumulation of autophagosomes in a Beclin1 and ATG7-dependent manner.146 Ca2+ released from the ER triggers the activation of calmodulin-dependent protein kinase kinase-2, leading to the activation of AMPK to facilitate autophagy.147, 148 Moreover, ER-derived calcium release can also stimulate the activation of PKC, resulting in the upregulation of the LC3Ⅱ/LC3Ⅰ ratio149 and the activation of JNK,150 both of which promote autophagy via mTOR-independent pathways.151 Furthermore, DAPK is activated by calcium release and contributes to Beclin1 phosphorylation, disrupting the Beclin1/BCL-2 complex and initiating autophagy.152 The interactions between autophagy and apoptosis mediated by ERS Numerous studies have demonstrated that the processes of autophagy and apoptosis, regulated by ERS, are interconnected rather than independent, resulting in a complex regulatory network with crosstalk at various levels45 (Figure 6). Normal human cartilage exhibits elevated expression of autophagy regulators such as ULK1, Beclin1, and LC3-II, suggesting that autophagy serves as a protective mechanism in maintaining cartilage homeostasis.23 Autophagy plays a crucial role in removing harmful substances that contribute to articular cartilage degeneration and in protecting chondrocytes, thus potentially delaying the progression of OA. The upregulation of autophagy markers in mild OA cartilage compared to non-OA cartilage suggests a potential adaptive response to protect cells during OA progression. However, autophagic flux is diminished in late-stage OA.153 While under certain circumstances, autophagy may inhibit chondrocyte apoptosis and enhance cell survival, excessive autophagy can actually increase chondrocyte apoptosis rates. The intricate interplay between these processes ultimately contributes to the exacerbation of articular cartilage degeneration. Apoptosis is typically characterized by elevated levels of caspase activation, particularly involving caspase-8, caspase-3, and calpain, resulting in the cleavage of autophagic proteins, suppression of the autophagic process, cessation of cytoprotective mechanisms, and promotion of apoptosis.154 While autophagy is generally supportive of cell viability, the induction of apoptosis ultimately results in programmed cell death. Consequently, this interplay plays a pivotal role in the cellular response to ERS.Fig. 6A schematic representation of the common upstream signaling pathways of autophagy and apoptosis under ERS. Under the condition of ERS, PERK is triggered, leading to its phosphorylation and subsequent inactivation of eIF2α. Consequently, this triggers the specific initiation of ATF4, which promotes autophagy and apoptosis. ATF4 not only stimulates autophagy by inducing various ATG genes but also facilitates apoptosis by degrading XIAP and collaborating with CHOP during prolonged ERS. CHOP initiates the apoptotic response by regulating pro-apoptotic proteins such as BIM and DR5, as well as anti-apoptotic proteins like Bcl-2, and by facilitating Ca2+ release through ERO1. IRE1α forms a complex with TRAF2 and ASK1, thereby inducing downstream activation of JNK signaling pathway and facilitating the processes of autophagy and apoptosis. ATF6 indirectly modulates autophagy or apoptosis through XBP-1 and CHOP. Disruption of Ca2+ homeostasis by ERS is additionally implicated in the initiation of autophagy and apoptosis. This figure is created with BioRender.com. Abbreviations used: ATF4, activating transcription factor 4; CHOP, C/EBP homologous protein; ERO1, endoplasmic reticulum oxidase 1; ERS, endoplasmic reticulum stress; IRE1, inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase; PERK, protein kinase-like ER kinase; XIAP, X-linked inhibitor of apoptosis protein.Fig. 6 A schematic representation of the common upstream signaling pathways of autophagy and apoptosis under ERS. Under the condition of ERS, PERK is triggered, leading to its phosphorylation and subsequent inactivation of eIF2α. Consequently, this triggers the specific initiation of ATF4, which promotes autophagy and apoptosis. ATF4 not only stimulates autophagy by inducing various ATG genes but also facilitates apoptosis by degrading XIAP and collaborating with CHOP during prolonged ERS. CHOP initiates the apoptotic response by regulating pro-apoptotic proteins such as BIM and DR5, as well as anti-apoptotic proteins like Bcl-2, and by facilitating Ca2+ release through ERO1. IRE1α forms a complex with TRAF2 and ASK1, thereby inducing downstream activation of JNK signaling pathway and facilitating the processes of autophagy and apoptosis. ATF6 indirectly modulates autophagy or apoptosis through XBP-1 and CHOP. Disruption of Ca2+ homeostasis by ERS is additionally implicated in the initiation of autophagy and apoptosis. This figure is created with BioRender.com. Abbreviations used: ATF4, activating transcription factor 4; CHOP, C/EBP homologous protein; ERO1, endoplasmic reticulum oxidase 1; ERS, endoplasmic reticulum stress; IRE1, inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase; PERK, protein kinase-like ER kinase; XIAP, X-linked inhibitor of apoptosis protein. Autophagy and apoptosis typically co-occur within the same cell, with autophagy typically preceding apoptosis.155 This sequential relationship is attributed to ERS-inducing autophagy as a protective response, particularly in cases where ERS levels are not severe enough to trigger apoptosis. Conversely, when ERS surpasses a critical threshold in terms of duration or intensity, both apoptotic and non-apoptotic lethal pathways are activated.156 Fluctuations in the activation of autophagy-dependent survival and apoptotic mechanisms have been noted in response to varying levels of ERS.157 Specifically, it was observed that low levels of ERS typically induced autophagy, whereas high levels of ERS triggered a transient activation of autophagy followed by apoptosis. Additionally, autophagy was rapidly suppressed during the activation of apoptosis at high ERS levels This indicates that the process of self-destruction is initiated in a swift manner when ERS levels surpass a certain threshold, potentially leading to the deactivation of autophagy as cells enter apoptosis. This phenomenon may be attributed to the caspase-mediated breakdown of autophagic proteins.158 Furthermore, under specific conditions, autophagy or its associated proteins may facilitate apoptosis by degrading vital cellular components or facilitating the activation of apoptotic and necrotic pathways.159 Tunicamycin has been demonstrated to induce ERS, as evidenced by the upregulation of chaperone proteins GRP78 and GRP94, as well as increased phosphorylation of elF2α. Research has shown that ERS induced by tunicamycin can result in both apoptosis and autophagy of chondrocytes, with pretreatment using the autophagy inhibitor 3-methyladenine exacerbating chondrocyte apoptosis.160 Studies have indicated that the activation of autophagy can provide a certain level of protection for chondrocytes against ERS-induced damage. Additionally, the expression of CHOP in chondrocytes was significantly enhanced by tunicamycin.,137 while the specific knockout of CHOP not only augmented autophagy but also notably decreased chondrocyte apoptosis.161 Hence, CHOP has the ability to facilitate ERS-induced apoptosis by suppressing autophagy. It has been proposed that the IRE1 and PERK pathways within the UPR play crucial roles in modulating the interplay between ERS-induced autophagy and apoptosis. The IRE1 and PERK pathways have been shown to facilitate the transcriptional up-regulation of numerous autophagy genes, such as p62. Suppression of either IRE1 or PERK can abolish the expression of these autophagy genes during ERS.162 This indicates the occurrence of a comprehensive transcriptional cascade primarily involving genes related to the autophagy pathway in response to ERS. Nevertheless, prolonged ERS can trigger the predominance of pro-apoptotic events, ultimately culminating in apoptosis. Activated IRE1 has the ability to recruit TRAF2, resulting in the activation of downstream JNK and PERK pathways, ultimately leading to the induction of CHOP for the regulation of apoptosis-related gene transcription. This process subsequently triggers MOMP and initiates the endogenous apoptotic program. Research indicates a significant interdependence between the IRE1 and PERK pathways, with studies demonstrating that silencing of PERK enhances cell viability during ERS and that the JNK-induced apoptosis mediated by IRE1 is attenuated in cells lacking PERK, suggesting a positive feedback mechanism between the two branches.163 Therefore, it is essential to consider the impact of ERS on cellular processes such as autophagy and apoptosis, as excessive ERS can trigger apoptosis while inducing autophagy-dependent survival. The interplay between autophagy and apoptosis in response to ERS plays a crucial role in maintaining cellular homeostasis. Given the involvement of ERS-induced autophagy and apoptosis in various diseases, including neurodegenerative diseases, malignant tumors, and diabetes, it is imperative to study the life-and-death decisions mediated by ERS. Currently, while there has been notable advancement in the comprehension of the interplay between ERS-mediated autophagy and apoptosis pathways, as well as their associated signaling networks, the practical implementation of this knowledge in clinical therapy remains constrained. Moving forward, it is imperative to delve deeper into the molecular mechanisms underlying ERS-induced autophagy and apoptosis, particularly in relation to OA, and to proactively pursue the development of targeted pharmacological agents with antagonistic properties. Such endeavors hold promise for introducing novel therapeutic modalities for various diseases. A treatment: targeting ERS to regulate chondrocyte apoptosis and autophagy OA is a complex disease with multiple contributing factors, one of which is the ERS-induced dynamic regulation of chondrocyte apoptosis and autophagy. Consequently, targeting ERS or modulating the UPR signaling pathways may hold promise for future OA treatment. In the following sections, therapeutic agents that target these potential pathways will be discussed. A table is presented here summarizing the drugs used to treat OA by modulating ERS (Table 1).Table 1Drugs for the treatment of OA by regulating ERS.Table 1CompoundsExperimental modelsTargeted ER moleculesPreclinical or clinical outcomesReferencesPanax quinquefolius saponinIL-1β-induced rat chondrocytesTG-induced rat chondrocytesACLT and DMM rat OA modelGRP78, CHOPAlleviated inflammation and apoptosis in chondrocytesAlleviated cartilage degeneration in rats164BaicalinOA patient-isolated chondrocytes treated with H2O2Patients with knee OA of Kellgren-Lawrence grade II or IIIPatients with moderate knee OAPatients with OAGRP78, CHOPProtected chondrocyte viabilityReduced sign and symptoms of OANo serious adverse effects related to Flavocoxid administrationImproved VAS score1651661671684-phenylbutyric acidACLT rat OA modelGRP78, CHOPAlleviated inflammation and apoptosis in chondrocytesAttenuated the progression of OA169CelastrolTM-induced rat chondrocytesACLT and DMM rat OA modelGRP78, ATF6, CHOP, XBP1Alleviated chondrocytes apoptosisAttenuated the progression of OA170Tauroursodeo-xycholic acidOA patient-isolated chondrocytes treated with TMGRP78, CHOPInhibited tunicamycin-induced apoptosis in chondrocytes171TaurineOA patient-isolated chondrocytes treated with H2O2GRP78, CHOPAlleviated chondrocytes apoptosis172MelatoninOA patient-derived chondrocytes treated with LPSACLT rat OA modelIRE1α-XBP1s-CHOP axisAlleviated chondrocytes apoptosisAlleviated chondrocytes apoptosis and attenuated the progression of OA173DapagliflozinIL-1β induced rat chondrocytesDMM rat OA modelGRP78, PERK-eIF2α-CHOP axisAlleviated chondrocytes apoptosisAlleviated inflammation and cartilage degeneration in OA rat174CurcuminTBHP-induced rat chondrocytesACLT rat OA modelPatients with knee OA of Kellgren-Lawrence grade II or IIIPatients with mild to moderate knee OAPatients with knee OAPatients with knee OAPatients with knee OAGRP78, PERK-eIF2α-CHOP axisAlleviated TBHP-induced cytotoxicity and apoptosisAlleviated chondrocytes and proteoglycan loss and inhibited the progression of OA (joint space narrowing)Lowered knee pain VAS score compared to placebo groupLowered WOMAC, VAS and LPFI scores compared to placeboReduced pain and improved KOOS15175176177178179EchinacosideTBHP-induced rat chondrocytesDMM rat OA modelGRP78,PERK-eIF2α-CHOP axisAlleviated chondrocytes apoptosisAlleviated cartilage degeneration180SafranalTBHP-induced rat chondrocytesDMM rat OA modelGRP78, ATF6, IRE1α, XBP-1, PERK, eIF2α, ATF4, CHOPAlleviated chondrocytes apoptosisAttenuated the progression of OA181SulforaphaneH2O2-induced rat chondrocytesDMM rat OA modelCHOP, GRP78Alleviated chondrocytes apoptosisAttenuated the progression of OA182QuercetinTBHP-induced rat chondrocytesDMM OA rat modelPatients with knee OAGRP78, CHOP, ATF6,p-PERK/PERKp-IRE1α/ IRE1αAlleviated chondrocytes apoptosisInhibited cartilage degeneration and chondrocytes apoptosis in the knee joints183Improved OA-associated symptoms based on JOA criteria and self-recorded VAS pain subscalesImproved type II collagen synthesis/ degradation184SalicinTNF-α-induced rat chondrocytesACLT rat OA modelGRP78, p-IRE1α/ IRE1αEnhancing chondrocyte proliferation and inhibiting chondrocyte apoptosisReversed ACLT-induced cartilage degeneration.185VitexinIL-1ß-induced OA rat chondrocytesACLT and DMM rat OA modelOA patient-derived chondrocytesGRP78, CHOPAlleviated IL-1ß-induced apoptosis and inflammation in chondrocytesAttenuated the progression of OA186Alleviated IL-1β-induced inflammatory responses in chondrocytes187TetramethylpyrazineTG-induced rat chondrocytesCHOP, GRP78Ameliorated inflammation and cartilage degeneration188SalidrosidTNF-α-treated human OA chondrocytesDMM mouse OA modelCHOPAlleviated TNF-α-induced inflammatory response and ERS-related apoptosisDecreased apoptosis, inflammation, and attenuation of OA development189DiazoxideH2O2-induced rat chondrocytesACLT and DMM rat OA modelCHOP, ATF6Alleviated chondrocyte apoptosisAlleviated cartilage degeneration190Achyranthes bidentata polysaccharidesTG-induced rat chondrocytesACLT and DMM rat OA modelPERK, GRP78, ATF4, CHOPAlleviated chondrocyte apoptosisPromoted the repair of articular cartilage in OA mice191miR-486-5pIL-1ß-induced OA rat chondrocytesDMM rat OA modelCHOP, GRP78Alleviated chondrocyte apoptosisAtenuated rat OA progression18Duhuo Jisheng decoctionTM-induced rat chondrocytesGRP78 ATF4, CHOP, XBP1Enhanced the viability of chondrocytes exposed to TM and alleviated chondrocyte apoptosis192Alpha-lipoic acidMIA-induced OA miceGRP78, ATF4, CHOPAlleviated cartilage degeneration in mice193ResveratrolTetracycline-induced OA miceHealthy postmenopausal womenHealthy postmenopausal womenPatients with knee OACHOPAlleviated cartilage degeneration and ameliorated OA development in miceReduced chronic pain in age-related OAReduced chronic pain in age-related OAImproved pain, functions, and associated symptoms14194195196Safflower yellowTNF-α-treated rat chondrocytesACLT rat OA modelPERK, IRE1α, GRP78Restored cell proliferation and suppressed inflammation by inhibiting TNF-α induced activation of NF-κBInhibited cartilage degeneration197TrehaloseTBHP-treated mouse and human chondrocytesDMM mouse OA modelGRP78, CHOPPromoted autophagy and inhibited TBHP-induced apoptosis in chondrocytesAmeliorated OA development198GYY4137 (A donor of H2S)TBHP-induced rat chondrocytesGRP78, CHOPPromoted autophagy and inhibited TBHP-induced apoptosis in chondrocytes133Abbreviations used: TM, Tunicamycin; TG, Thapsigargin; TBHP, Tert-butyl Hydroperoxide; LPS, Lipopolysaccharides; TNF-α, Tumor necrosis factor-α; MIA, Mono-iodoacetate; ACLT, Anterior cruciate ligament transection; DMM, Destabilization of medial meniscus. Table 1Drugs for the treatment of OA by regulating ERS.Table 1CompoundsExperimental modelsTargeted ER moleculesPreclinical or clinical outcomesReferencesPanax quinquefolius saponinIL-1β-induced rat chondrocytesTG-induced rat chondrocytesACLT and DMM rat OA modelGRP78, CHOPAlleviated inflammation and apoptosis in chondrocytesAlleviated cartilage degeneration in rats164BaicalinOA patient-isolated chondrocytes treated with H2O2Patients with knee OA of Kellgren-Lawrence grade II or IIIPatients with moderate knee OAPatients with OAGRP78, CHOPProtected chondrocyte viabilityReduced sign and symptoms of OANo serious adverse effects related to Flavocoxid administrationImproved VAS score1651661671684-phenylbutyric acidACLT rat OA modelGRP78, CHOPAlleviated inflammation and apoptosis in chondrocytesAttenuated the progression of OA169CelastrolTM-induced rat chondrocytesACLT and DMM rat OA modelGRP78, ATF6, CHOP, XBP1Alleviated chondrocytes apoptosisAttenuated the progression of OA170Tauroursodeo-xycholic acidOA patient-isolated chondrocytes treated with TMGRP78, CHOPInhibited tunicamycin-induced apoptosis in chondrocytes171TaurineOA patient-isolated chondrocytes treated with H2O2GRP78, CHOPAlleviated chondrocytes apoptosis172MelatoninOA patient-derived chondrocytes treated with LPSACLT rat OA modelIRE1α-XBP1s-CHOP axisAlleviated chondrocytes apoptosisAlleviated chondrocytes apoptosis and attenuated the progression of OA173DapagliflozinIL-1β induced rat chondrocytesDMM rat OA modelGRP78, PERK-eIF2α-CHOP axisAlleviated chondrocytes apoptosisAlleviated inflammation and cartilage degeneration in OA rat174CurcuminTBHP-induced rat chondrocytesACLT rat OA modelPatients with knee OA of Kellgren-Lawrence grade II or IIIPatients with mild to moderate knee OAPatients with knee OAPatients with knee OAPatients with knee OAGRP78, PERK-eIF2α-CHOP axisAlleviated TBHP-induced cytotoxicity and apoptosisAlleviated chondrocytes and proteoglycan loss and inhibited the progression of OA (joint space narrowing)Lowered knee pain VAS score compared to placebo groupLowered WOMAC, VAS and LPFI scores compared to placeboReduced pain and improved KOOS15175176177178179EchinacosideTBHP-induced rat chondrocytesDMM rat OA modelGRP78,PERK-eIF2α-CHOP axisAlleviated chondrocytes apoptosisAlleviated cartilage degeneration180SafranalTBHP-induced rat chondrocytesDMM rat OA modelGRP78, ATF6, IRE1α, XBP-1, PERK, eIF2α, ATF4, CHOPAlleviated chondrocytes apoptosisAttenuated the progression of OA181SulforaphaneH2O2-induced rat chondrocytesDMM rat OA modelCHOP, GRP78Alleviated chondrocytes apoptosisAttenuated the progression of OA182QuercetinTBHP-induced rat chondrocytesDMM OA rat modelPatients with knee OAGRP78, CHOP, ATF6,p-PERK/PERKp-IRE1α/ IRE1αAlleviated chondrocytes apoptosisInhibited cartilage degeneration and chondrocytes apoptosis in the knee joints183Improved OA-associated symptoms based on JOA criteria and self-recorded VAS pain subscalesImproved type II collagen synthesis/ degradation184SalicinTNF-α-induced rat chondrocytesACLT rat OA modelGRP78, p-IRE1α/ IRE1αEnhancing chondrocyte proliferation and inhibiting chondrocyte apoptosisReversed ACLT-induced cartilage degeneration.185VitexinIL-1ß-induced OA rat chondrocytesACLT and DMM rat OA modelOA patient-derived chondrocytesGRP78, CHOPAlleviated IL-1ß-induced apoptosis and inflammation in chondrocytesAttenuated the progression of OA186Alleviated IL-1β-induced inflammatory responses in chondrocytes187TetramethylpyrazineTG-induced rat chondrocytesCHOP, GRP78Ameliorated inflammation and cartilage degeneration188SalidrosidTNF-α-treated human OA chondrocytesDMM mouse OA modelCHOPAlleviated TNF-α-induced inflammatory response and ERS-related apoptosisDecreased apoptosis, inflammation, and attenuation of OA development189DiazoxideH2O2-induced rat chondrocytesACLT and DMM rat OA modelCHOP, ATF6Alleviated chondrocyte apoptosisAlleviated cartilage degeneration190Achyranthes bidentata polysaccharidesTG-induced rat chondrocytesACLT and DMM rat OA modelPERK, GRP78, ATF4, CHOPAlleviated chondrocyte apoptosisPromoted the repair of articular cartilage in OA mice191miR-486-5pIL-1ß-induced OA rat chondrocytesDMM rat OA modelCHOP, GRP78Alleviated chondrocyte apoptosisAtenuated rat OA progression18Duhuo Jisheng decoctionTM-induced rat chondrocytesGRP78 ATF4, CHOP, XBP1Enhanced the viability of chondrocytes exposed to TM and alleviated chondrocyte apoptosis192Alpha-lipoic acidMIA-induced OA miceGRP78, ATF4, CHOPAlleviated cartilage degeneration in mice193ResveratrolTetracycline-induced OA miceHealthy postmenopausal womenHealthy postmenopausal womenPatients with knee OACHOPAlleviated cartilage degeneration and ameliorated OA development in miceReduced chronic pain in age-related OAReduced chronic pain in age-related OAImproved pain, functions, and associated symptoms14194195196Safflower yellowTNF-α-treated rat chondrocytesACLT rat OA modelPERK, IRE1α, GRP78Restored cell proliferation and suppressed inflammation by inhibiting TNF-α induced activation of NF-κBInhibited cartilage degeneration197TrehaloseTBHP-treated mouse and human chondrocytesDMM mouse OA modelGRP78, CHOPPromoted autophagy and inhibited TBHP-induced apoptosis in chondrocytesAmeliorated OA development198GYY4137 (A donor of H2S)TBHP-induced rat chondrocytesGRP78, CHOPPromoted autophagy and inhibited TBHP-induced apoptosis in chondrocytes133Abbreviations used: TM, Tunicamycin; TG, Thapsigargin; TBHP, Tert-butyl Hydroperoxide; LPS, Lipopolysaccharides; TNF-α, Tumor necrosis factor-α; MIA, Mono-iodoacetate; ACLT, Anterior cruciate ligament transection; DMM, Destabilization of medial meniscus. Drugs for the treatment of OA by regulating ERS. Abbreviations used: TM, Tunicamycin; TG, Thapsigargin; TBHP, Tert-butyl Hydroperoxide; LPS, Lipopolysaccharides; TNF-α, Tumor necrosis factor-α; MIA, Mono-iodoacetate; ACLT, Anterior cruciate ligament transection; DMM, Destabilization of medial meniscus. Chondrocytes, as the sole cellular constituents of articular cartilage, are pivotal in regulating cartilage metabolism. The reduction of the chondrocyte population due to apoptosis is a significant pathological feature of OA. ERS serves as an intrinsic trigger for apoptosis, with its activated pathway playing a crucial role in the apoptotic process of OA chondrocytes. By employing effective strategies to inhibit ERS, the apoptosis of chondrocytes can be mitigated, thereby reducing cartilage degradation in OA patients and ultimately achieving the goal of OA prevention and treatment. IRE1 and PERK have the ability to regulate the expression of apoptotic proteins such as GRP78, CHOP, and p53, ultimately inducing chondrocytes to activate the apoptotic pathway. Additionally, the relationship between ERS and oxidative stress is reciprocal, as the accumulation of unfolded proteins in the ER lumen can stimulate ROS production, subsequently promoting oxidative stress. This increased oxidative stress further disrupts ER folding function, leading to the accumulation and oxidation of misfolded proteins, exacerbating ERS and ultimately triggering cell death in a continuous cycle.199 In the future, investigating the role of ERS-mediated apoptosis and oxidative stress in OA may present a novel therapeutic approach for the management of OA. There exists a complex interplay between ERS and autophagy in OA. In instances where UPR, ERAD, and other ERS regulatory mechanisms fail to restore ER homeostasis, autophagy may be upregulated as a compensatory mechanism to eliminate aberrant proteins and damaged ER structures resulting from ERS, thereby regulating ER quality and quantity.200 Previous research has identified two main forms of ERS-induced autophagy: ERS-mediated autophagy and ER-phagy. Inhibition or activation of ERS resulted in alterations in the protein expression levels of autophagy markers LC3II, Beclin-1, and p62, indicating a potential association with ERS-mediated autophagy.47 ERS is capable of stimulating autophagy through the UPR pathway, as well as triggering autophagy by facilitating calcium efflux and suppressing BCL-2 activity. While autophagy plays a protective role in response to ERS, prolonged or intensified ERS can lead to autophagy-dependent apoptosis and subsequent cellular damage.201 Therefore, the impact of ERS-induced autophagy on chondrocyte viability exhibits heterogeneity, manifesting both pro-survival and pro-death outcomes. This variability may be attributed not only to the various stages of OA but also to the intensity and duration of ERS and autophagy activation. A comprehensive investigation into the interplay between ERS and autophagy in OA could potentially inform future therapeutic strategies for the management of OA. An increasing body of research indicates that the promotion of autophagy serves as a crucial mechanism in various OA treatment modalities, such as pharmaceutical interventions, physical therapy, and biological therapies. This approach has the potential to slow the advancement of OA by augmenting autophagic activity in chondrocytes, thereby averting chondrocyte demise, mitigating ECM degradation, and diminishing inflammatory reactions. It is noteworthy that certain drugs can modulate cellular activities by interacting with molecular chaperones in the ER. One notable example is curcumin. Multiple studies202, 203 have reported that curcumin binds to heat shock protein 90 (HSP90). Notably, HSP90 is essential for the induction of autophagy through reciprocal regulation with ULK1.204 This type of regulation does not follow the classical ERS regulatory pathways, such as the UPR, and is therefore excluded from the table. Problems and Prospects The pathogenesis of OA is multifaceted and encompasses a wide range of risk factors, including but not limited to aging, obesity, traumatic injury, oxidative stress, inflammation, cell death, and dysregulated autophagy. Current treatment options for OA primarily consist of pharmacological interventions and surgical procedures. Pharmacological therapies encompass the use of nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, and central analgesics for symptom management, while supplements like glucosamine, hyaluronic acid, and chondroitin sulfate are utilized to preserve cartilage integrity.205 NSAIDs have been demonstrated to elevate the likelihood of gastrointestinal and cardiovascular complications. Meanwhile, the effectiveness of oral dietary supplements containing glucosamine, hyaluronic acid, and chondroitin sulfate remains uncertain based on clinical trial evidence.206 In cases where conservative therapies prove ineffective, surgical interventions such as subchondral bone microfracture, autologous chondrocyte implantation, and knee replacement may be considered; however, these procedures impose a significant financial burden on individuals, families, and society as a whole. Nevertheless, while these therapeutic strategies focus on alleviating symptoms, they may not address the root cause of OA progression. Therefore, early intervention in the disease progression, aimed at reducing cartilage damage and promoting the regeneration of impaired cartilage, is currently a key objective in the treatment of OA. The exacerbation of OA is significantly influenced by aging and obesity, both of which are also recognized as risk factors for ERS.207, 208 Currently, it has been established that ERS-induced chondrocyte apoptosis plays a crucial role in the progression of articular cartilage degeneration in OA. The excessive degradation of the ECM serves as both the initiating and exacerbating factor of ERS. Simultaneously, the activation of the UPR provides some relief from ERS, but under conditions of high-intensity ERS, it can contribute to the exacerbation of cell apoptosis and inflammation. ERS intensifies with the progression of OA, as the ongoing destruction and degeneration of cartilage further exacerbate the condition. Given the potential association between dysregulation of the ERS/UPR axis and the progression of OA, targeting this pathway could offer a promising and innovative approach to OA treatment. The precise role of the UPR, a key pathway governed by ERS, in the progression of OA, remains ambiguous, as UPR activation may either facilitate or impede OA progression, while diminished UPR activity could result in compromised ERS response, continual accumulation of misfolded proteins, disrupted autophagy, and diminished antioxidant capacity. Hence, it can be reasonably deduced that the UPR condition of individuals with OA might exhibit variability. Research has demonstrated that pharmaceutical agents aimed at ERS, including natural herbal drugs, synthetic chemicals, and traditional Chinese medicine compound agents, have the ability to decrease chondrocyte apoptosis, promote protective autophagy, and suppress excessive autophagy through ERS inhibition, ultimately serving a protective function in cartilage. There remain deficiencies in the existing research, notably in the limited exploration of drugs that modulate chondrocyte autophagy through interference with the ERS-autophagy pathway. Furthermore, the current focus on specific proteins and molecules in the detection of ERS-related pathways lacks precision indicators and theoretical coherence, neglecting comprehensive association research among pathways. ERS regulatory pathways show promise in mitigating symptoms of OA, targeting the disease to halt or prevent its progression, and reducing the exacerbation of symptoms associated with OA. It should be emphasized that inhibiting the UPR pathway may lead to unintended consequences, such as hindering the production of ER molecules involved in protein folding, potentially perpetuating protein misfolding, and resulting in unpredictable and severe outcomes. In the clinical setting, the identification of drug targets and associated clinical biomarkers pertaining to specific mechanisms underlying various pathological changes in patients with OA may facilitate personalized treatment tailoring for this disease. The comprehensive elucidation of the relationship between OA grading systems, such as the Kellgren-Lawrence grading scale and Outerbridge Classification, and biomarker status associated with ERS remains incomplete. With the availability of different ERS inhibitors that target specific pathways, comprehending the significance of these markers can aid in the prompt identification and tailored precision therapy for patients exhibiting these particular proteins. It is noteworthy that the impact of ERS inhibitor therapy demonstrates chondroprotective and anti-chondrocyte apoptotic effects in certain models, yet exhibits pro-apoptotic or pro-autophagic effects in others. The inadequate selectivity of free ERS modulators contributes to their propensity for aggregation in non-disease tissues or cells, resulting in potential systemic side effects, diminished bioavailability, and decreased efficacy. For instance, the transport of the tauroursodeoxycholic acid into cells through the Na+/taurocholate cotransporter, which is prominently expressed on hepatocytes, increases the likelihood of off-target effects.209 The utilization of drug delivery systems incorporating ERS modulators for targeted, prolonged, and safe drug delivery to disease sites presents a promising therapeutic approach. Furthermore, due to the limited half-life and rapid metabolism of many small molecules and biological agents, such as melatonin,210 achieving optimal therapeutic outcomes through oral, intravenous, or intraarticular administration is challenging. Consequently, a sustained drug delivery system may be necessary to effectively modify the progression of OA. The intricate nature of OA pathogenesis and the varied clinical presentations suggest that targeting a singular therapeutic pathway may not be adequate in addressing the inflammatory joint milieu and facilitating articular cartilage repair. Numerous studies have elucidated the potential involvement of ERS in OA, yet the precise underlying mechanism remains elusive. Further investigations are warranted to delineate the molecular pathways through which ERS influences chondrocyte viability and apoptosis and to elucidate its interplay with the pathophysiological mechanisms of OA. Furthermore, further exploration is warranted to elucidate the specific regulatory role of ERS in chondrocyte autophagy. The processes of autophagy and apoptosis in chondrocytes play a crucial role in the maintenance of articular cartilage homeostasis and function. Subsequent research efforts should prioritize elucidating the interplay between autophagy and apoptosis in chondrocytes, as well as their impact on OA progression. Given the variability of the pathological process of OA among individuals, it is imperative for future research to investigate the distinct roles of ERS, chondrocyte autophagy, and apoptosis in various types and stages of OA through the lens of precision medicine. By leveraging these disparities, the formulation of personalized diagnostic and therapeutic approaches has the potential to greatly enhance the efficacy of OA treatment. Currently, the majority of studies examining targeted ERS for the management of OA are limited to laboratory environments and necessitate translation into clinical applications. The signaling pathways involved in ERS-mediated chondrocyte autophagy and apoptosis have been identified as potential targets for therapeutic drug development. However, the potential adverse reactions and complications associated with intervening in these pathways remain unclear. Further research is needed to investigate the co-regulation mechanism and clinical implications of apoptosis and autophagy in OA chondrocytes undergoing ERS. Ethics statement Not applicable. Funding and support Financial supports from National Natural Science Foundation of China (No. 82072425, 81873991, and 81672238); the Program of Jiangsu Science and Technology Department (No. BK20211083, BE2022737), the Program of Suzhou Health Commission (No. GSWS2020078 and SZXK202111), the Program of Suzhou Science and Technology Department (SKY2023062), and Jiangsu Graduate Student Cultivation Innovative Engineering Graduate Research and Practice Innovation Program (No. SJCX23_0683, No. SJCX23_0684). Author contributions Yifan Lu: Data curation, Formal analysis, Software, Writing – original draft, Writing – review & editing. Jing Zhou: Conceptualization, Resources, Writing – review & editing. Hong Wang: Investigation, Methodology, Investigation, Writing – review & editing. Hua Gao: Formal analysis, Visualization. Eryu Ning: Data curation, Project administration. Zhiqiang Shao: Data curation, Formal analysis. Yuefeng Hao: Funding acquisition, Writing – review & editing. Xing Yang: Formal analysis, Funding acquisition, Supervision. Declarations of interest The authors declare that there is no conflict of interest.